Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

NCT00836043 · clinicaltrials.gov ↗

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to low enrollment.

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Alemtuzumab (MabCampath)

Sponsor

Genzyme, a Sanofi Company